Rezafungin: A Review in Invasive Candidiasis

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Invasive candidiasis presents a significant health challenge, often requiring prolonged antifungal therapy.
• First-generation echinocandins necessitate daily intravenous administration, impacting patient convenience and healthcare resources.
• Rezafungin represents a novel echinocandin with enhanced pharmacokinetic properties.

Purpose of the Study:

• To evaluate the efficacy and safety of rezafungin compared to caspofungin for invasive candidiasis.
• To assess the clinical utility of once-weekly rezafungin administration.

Main Methods:

• Phase 3 ReSTORE trial involving adults with candidaemia or invasive candidiasis.
• Comparison of rezafungin (once-weekly) versus caspofungin (once-daily).
• Assessment of global cure rates at day 14 and all-cause mortality at day 30.

Main Results:

• Rezafungin was non-inferior to caspofungin in achieving global cure rates and reducing all-cause mortality.
• Once-weekly rezafungin administration potentially allows for earlier infection clearance.
• Rezafungin was generally well tolerated, with manageable adverse events like hypokalaemia and pyrexia.

Conclusions:

• Rezafungin is a safe and effective treatment for invasive candidiasis in adults.
• Its once-weekly dosing offers a significant advantage over daily administration of older echinocandins.
• Rezafungin expands therapeutic options for invasive fungal infections.